non-small cell lung, Patients with metastatic tumours (colorectal, renal and sarcoma)
Conditions
Brief summary
One year-Progression-free survival rate is defined as the rate of patients alive and free of progression at one year. Progression is defined using RECIST 1.1. criteria, or death, whatever the cause of death, whichever occurs first
Detailed description
Efficacy: Progression-free survival (PFS) measured from the date of treatment initiation to date of progression or death whichever comes first. Patients alive and free of progression at the cut-off date will be censored at the last assessment date Tumour response indicators and clinical endpoints, assessed according to RECIST v 1.1 and modified RECIST (see synopsis), Toxicity : NCI- CTCAE V4.03 scale Toxicity is adverse events graded with the NCI-CTC-AE v4.03 scale, at least possibly related to the treatment., For patients with lung cancer and sarcoma receiving a second SABR course for oligoprogression(see synopsis)
Interventions
DRUGATEZOLIZUMAB
Sponsors
Institut Gustave Roussy
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| One year-Progression-free survival rate is defined as the rate of patients alive and free of progression at one year. Progression is defined using RECIST 1.1. criteria, or death, whatever the cause of death, whichever occurs first | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy: Progression-free survival (PFS) measured from the date of treatment initiation to date of progression or death whichever comes first. Patients alive and free of progression at the cut-off date will be censored at the last assessment date Tumour response indicators and clinical endpoints, assessed according to RECIST v 1.1 and modified RECIST (see synopsis), Toxicity : NCI- CTCAE V4.03 scale Toxicity is adverse events graded with the NCI-CTC-AE v4.03 scale, at least possibly related to the treatment., For patients with lung cancer and sarcoma receiving a second SABR course for oligoprogression(see synopsis) | — |
Countries
France
Outcome results
None listed